Two Sigma Investments, LP Praxis Precision Medicines, Inc. Transaction History

Two Sigma Investments, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.71 $38,976 - $76,608	44,800 Added 370.25%	56,900 $97,000
Q2 2023 Aug 14, 2023	SELL	$0.83 - $1.18 $33,781 - $48,026	-40,700 Reduced 77.08%	12,100 $13,000
Q1 2023 May 15, 2023	SELL	$0.8 - $4.98 $180,777 - $1.13 Million	-225,972 Reduced 81.06%	52,800 $42,000
Q4 2022 Feb 14, 2023	SELL	$1.88 - $2.49 $306,844 - $406,405	-163,215 Reduced 36.93%	278,772 $663,000
Q3 2022 Nov 14, 2022	BUY	$2.5 - $4.77 $95,887 - $182,953	38,355 Added 9.5%	441,987 $1 Million

Q2 2022 Aug 15, 2022	BUY	$1.75 - $11.34 $506,395 - $3.28 Million	289,369 Added 253.25%	403,632 $989,000
Q1 2022 May 16, 2022	SELL	$10.21 - $20.29 $386,938 - $768,950	-37,898 Reduced 24.91%	114,263 $1.17 Million
Q4 2021 Feb 14, 2022	BUY	$16.76 - $22.99 $428,268 - $587,463	25,553 Added 20.18%	152,161 $3 Million
Q3 2021 Nov 15, 2021	SELL	$13.15 - $22.56 $758,544 - $1.3 Million	-57,684 Reduced 31.3%	126,608 $2.34 Million
Q2 2021 Aug 16, 2021	BUY	$18.28 - $33.05 $3.37 Million - $6.09 Million	184,292 New	184,292 $3.37 Million

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $1.79B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.